Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.
Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Tabernero J, et al. Among authors: ramos fj. J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. J Clin Oncol. 2008. PMID: 18332469 Clinical Trial.
Aurora kinase family: a new target for anticancer drug.
Macarulla T, Ramos FJ, Tabernero J. Macarulla T, et al. Among authors: ramos fj. Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):114-22. doi: 10.2174/157489208784638785. Recent Pat Anticancer Drug Discov. 2008. PMID: 18537754 Review.
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F. Tabernero J, et al. Among authors: ramos fj. J Clin Oncol. 2010 Mar 1;28(7):1181-9. doi: 10.1200/JCO.2009.22.6043. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100964 Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J. Eskens FA, et al. Among authors: ramos fj. Clin Cancer Res. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. Epub 2013 Aug 27. Clin Cancer Res. 2013. PMID: 23983259 Clinical Trial.
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Tabernero J, et al. Among authors: ramos fj. Ann Oncol. 2010 Jul;21(7):1537-1545. doi: 10.1093/annonc/mdp549. Epub 2009 Nov 25. Ann Oncol. 2010. PMID: 19940007 Free article. Clinical Trial.
Novel targets in gastric and esophageal cancer.
Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J. Valverde CM, et al. Among authors: ramos fj. Crit Rev Oncol Hematol. 2006 Aug;59(2):128-38. doi: 10.1016/j.critrevonc.2006.02.001. Epub 2006 Jul 10. Crit Rev Oncol Hematol. 2006. PMID: 16829119
169 results